Until now all PD-(L)1 blockers were assumed to have broadly similar activity, with any differences being put down to trial design; the latest renal cancer data could…
In the Keynote-426 study Merck & Co’s Keytruda looks to have blasted Opdivo out of the water, showing a 47% reduction in risk of death versus Sutent.
Amgen has set the stage for low-hassle access to new cholesterol-lowering agents, leaving little choice for competitors.
Merck & Co awaits full Keynote-426 data with Keytruda plus Inlyta, while Seattle Genetics looks beyond Adcetris with enfortumab vedotin.
In a constrained pricing environment a volume play could help sales of Lilly's Emgality as it takes on Amgen’s Aimovig and Teva’s Ajovy.
Positive progression-free survival results in breast cancer for the company’s lead asset, margetuximab, take the markets by surprise.
One day after Biogen expands aducanumab trials, a canary in the coal mine, the rival crenezumab, fails in phase III.
Data from quad therapy and a subcutaneous formulation could resuscitate enthusiasm even if the US government shutdown delays Darzalex's upcoming first-line approval.
Issues with manufacturing, not exactly a new problem for Immunomedics, derail the company’s bid for glory.